AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Three ...
devdiscourse2d
Global Health Updates: A Week of Strides and Challenges
The latest health news includes China allowing foreign-owned hospitals in major cities, and the inclusion of AstraZeneca's ...
devdiscourse2d
Global Health Updates: China's New Policies and Emerging Outbreaks
Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...
The Pharma Letter2d
Enhertu added to China's health insurance plan
AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...
Nikkei Asia2d
Japan's Daiichi Sankyo to make cutting-edge cancer treatments in China
The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...
Daily2d
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
AstraZeneca's Enhertu breast cancer drug added to China's state insurance list
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...
Pharmaceutical Technology6d
Adcendo raises $135m as ADC funding frenzy continues
Founded in 2017 as a spin-out from the University of Copenhagen and Rigshospitalet, Adcendo previously raised $102.8m (€98m) ...
AstraZeneca PLC (AZN): Among the Most Promising Cancer Stocks According to Hedge Funds
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...